Last Updated: 25 Aug 2025
Source: Statifacts
The protein structure prediction tools market was valued at US$ 329.00 million in 2024 and is forecasted to hit US$ 4,070.10 million by 2034 with a CAGR of 28.6% during the period between 2025 and 2034. The advent of AI-powered platforms & visualization software, along with growing investment in precision medicine and drug discovery initiatives, is significantly contributing to the expansion of the industry.
The use of software as a service (SaaS) tools is allowing researchers to harness advanced visualization suites to conduct 3D streaming and real-time analysis using high-performance graphics and improve protein prediction results. Small and medium-sized biotechnology firms are combining cloud-based, integrated AI simulation platforms to model interactions, refine binding sites, and speed up prediction while simultaneously maintaining accuracy. Improvements in multi-omics integration have substantially improved throughput, allowing for the faster creation of completely new proteins which have the potential to revolutionize industrial enzymes, therapeutics.
Numerous collection processes capture inputs at multiple scales, e.g., gene and amino acid sequences, protein structures, and postulate interaction pathway involvement. These new breakthroughs are all expected to contribute significantly to the expansion of the protein structure prediction tools market.
By Application
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
Homology Modeling | 131.60 | 165.85 | 208.93 | 263.09 | 331.14 | 416.58 | 523.82 | 658.33 | 826.92 | 1,038.10 | 1,302.43 |
Ab Initio Modeling | 82.25 | 104.93 | 133.85 | 170.73 | 217.76 | 277.72 | 354.18 | 451.64 | 575.89 | 734.26 | 936.12 |
Machine Learning-Based Modeling | 115.15 | 152.31 | 201.32 | 265.89 | 350.93 | 462.87 | 610.13 | 803.77 | 1,058.26 | 1,392.57 | 1,831.55 |
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
Drug Development | 197.40 | 255.55 | 330.81 | 428.22 | 554.29 | 717.45 | 928.59 | 1,201.83 | 1,555.40 | 2,012.90 | 2,604.87 |
Biotechnology | 98.70 | 126.51 | 162.14 | 207.81 | 266.35 | 341.37 | 437.51 | 560.73 | 718.63 | 921 | 1,180.33 |
Others | 32.90 | 41.04 | 51.15 | 63.67 | 79.18 | 98.36 | 122.03 | 151.19 | 187.04 | 231.04 | 284.91 |
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
North America | 125.02 | 158.66 | 201.32 | 255.39 | 323.94 | 410.80 | 520.85 | 660.24 | 836.76 | 1,060.25 | 1,343.13 |
Europe | 98.70 | 129.89 | 170.85 | 224.61 | 295.14 | 387.66 | 508.94 | 667.89 | 876.14 | 1,148.87 | 1,505.94 |
Asia Pacific | 72.38 | 92.23 | 117.53 | 149.74 | 190.76 | 243.01 | 309.53 | 394.23 | 502.06 | 639.32 | 814.02 |
Latin America | 19.74 | 25.60 | 33.19 | 43.03 | 55.79 | 72.32 | 93.75 | 121.52 | 157.51 | 204.14 | 264.56 |
Middle East and Africa | 13.16 | 16.71 | 21.22 | 26.94 | 34.19 | 43.39 | 55.06 | 69.85 | 88.60 | 112.36 | 142.45 |
Last Updated: 25 Aug 2025
Source: Statifacts
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
Homology Modeling | 131.60 | 165.85 | 208.93 | 263.09 | 331.14 | 416.58 | 523.82 | 658.33 | 826.92 | 1,038.10 | 1,302.43 |
Ab Initio Modeling | 82.25 | 104.93 | 133.85 | 170.73 | 217.76 | 277.72 | 354.18 | 451.64 | 575.89 | 734.26 | 936.12 |
Machine Learning-Based Modeling | 115.15 | 152.31 | 201.32 | 265.89 | 350.93 | 462.87 | 610.13 | 803.77 | 1,058.26 | 1,392.57 | 1,831.55 |
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
Drug Development | 197.40 | 255.55 | 330.81 | 428.22 | 554.29 | 717.45 | 928.59 | 1,201.83 | 1,555.40 | 2,012.90 | 2,604.87 |
Biotechnology | 98.70 | 126.51 | 162.14 | 207.81 | 266.35 | 341.37 | 437.51 | 560.73 | 718.63 | 921 | 1,180.33 |
Others | 32.90 | 41.04 | 51.15 | 63.67 | 79.18 | 98.36 | 122.03 | 151.19 | 187.04 | 231.04 | 284.91 |
Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
---|---|---|---|---|---|---|---|---|---|---|---|
North America | 125.02 | 158.66 | 201.32 | 255.39 | 323.94 | 410.80 | 520.85 | 660.24 | 836.76 | 1,060.25 | 1,343.13 |
Europe | 98.70 | 129.89 | 170.85 | 224.61 | 295.14 | 387.66 | 508.94 | 667.89 | 876.14 | 1,148.87 | 1,505.94 |
Asia Pacific | 72.38 | 92.23 | 117.53 | 149.74 | 190.76 | 243.01 | 309.53 | 394.23 | 502.06 | 639.32 | 814.02 |
Latin America | 19.74 | 25.60 | 33.19 | 43.03 | 55.79 | 72.32 | 93.75 | 121.52 | 157.51 | 204.14 | 264.56 |
Middle East and Africa | 13.16 | 16.71 | 21.22 | 26.94 | 34.19 | 43.39 | 55.06 | 69.85 | 88.60 | 112.36 | 142.45 |
This market includes AI-driven platforms (such as AlphaFold, RoseTTAFold, I-TASSER, and Swiss-Model) that predict 3D protein structures from amino acid sequences. These tools accelerate understanding of molecular mechanisms, disease targets, and drug discovery pipelines by reducing reliance on traditional lab methods.
Demand is rising due to significant advances in AI-enabled accuracy, faster regulatory acceptance of computational models, increasing drug development investments, and broader adoption across pharmaceuticals, biotech, and academic research.
AlphaFold remains highly influential, with its latest version modeling complex interactions such as protein-DNA binding. Alternative platforms like RoseTTAFold, I-TASSER, and Swiss-Model continue to thrive, especially where open access and flexible pipelines matter.
North America holds the largest share thanks to deep biotech infrastructure and AI investment, while Asia-Pacific is the fastest-growing region, propelled by emerging healthcare R&D capabilities and supportive government initiatives.
Barriers include high computational costs, the need for expert talent, and ongoing needs for validation against experimental data. Exciting opportunities lie in diffusion-model AI frameworks, cloud-based scaling, integration with cryo-EM imaging, and democratization via managed services.
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Our customers work more efficiently and benefit from